ArticlePlant & cell physiology2025
The protein kinase inhibitor, tyrphostin AG126, and its derivatives suppress phosphorylation of plasma membrane H+-ATPase and light-induced stomatal opening.
Article in Plant & cell physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Phosphorylation of the penultimate residue, threonine (pen-Thr), of plasma membrane (PM) H+-ATPase is essential for its activation and blue light (BL)-induced stomatal opening. However, the regulatory mechanism of action of PM H+-ATPase pen-Thr phosphorylation is not completely understood. Here, we performed screening using a protein kinase inhibitor library and found that tyrphostin AG126 inhibited phosphorylation of PM H+-ATPase pen-Thr in guard cells in response to light and fungal toxin fusicoccin (FC), in addition to inhibition of light- and FC-induced stomatal opening. Analysis of the structure-activity relationship using AG126 derivatives (AGDs) revealed the hydroxyl group at the C-5 position of the compound to be essential for its activity. We further characterized one AG126 derivative, AGD-1, which effectively suppressed BL-induced stomatal opening with a half-inhibitory concentration of 2.0 μM. AGD-1 inhibited PM H+-ATPase pen-Thr phosphorylation in guard cells in response to BL and FC. In addition, AGD-1 suppressed FC-induced PM H+-ATPase pen-Thr phosphorylation in mesophyll cell protoplasts, implying that the effect of AGD-1 is not specific to guard cells. Furthermore, to improve the permeability of AGD-1, we synthesized acetylated AGD-1 (AcAGD-1), which was found to suppress BL- and FC-induced stomatal opening. AcAGD-1 suppressed light-induced PM H+-ATPase pen-Thr phosphorylation, but not Thr881 phosphorylation, in leaf discs, which is important for guard-cell PM H+-ATPase activation in addition to pen-Thr phosphorylation. This study identified a novel stomatal opening inhibitor capable of specifically inhibiting PM H+-ATPase pen-Thr phosphorylation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.